What's behind the push to make peptide therapies more readily available
Medical experts are raising concerns about the lack of clinical evidence for popular peptide therapies, which are currently being promoted in wellness circles. The FDA is set to review whether to allow compounding pharmacies to manufacture these substances, potentially ending their current grey-market status.
Why it matters
The decision could significantly impact public health safety and the accessibility of unvetted medical treatments in the U.S.
Every day, Dr. Alexander Weber finds himself fielding another round of questions about peptides — and whether the trendy therapies can help his patients recover from sports injuries or surgery.
The article presents both the medical establishment's skepticism and the political push for deregulation without taking a definitive stance.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in